Compass’ big psychedelic study doesn’t impress investors
Bio Pharma Dive
JUNE 23, 2025
While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s version of psilocybin could be as a depression treatment.
Let's personalize your content